Gilead Sciences Inc. (GILD) News Headlines

▮ More

Date

Headline

10/15/2019 8:51:54 AM Gilead Sciences Names Andrew Dickinson CFO - Quick Facts

10/15/2019 8:41:31 AM Gilead Sciences Names Andrew Dickinson CFO

10/11/2019 5:54:17 AM MITO Empowered, FPRX Cuts Another 70 Jobs, Second Death In Legionnaires Outbreak

10/8/2019 2:35:19 AM Gilead Announces NDA Submission For Filgotinib In Japan - Quick Facts

10/8/2019 2:29:27 AM Gilead Sciences Submits NDA For Filgotinib For Rheumatoid Arthritis In Japan

10/7/2019 8:34:24 AM Gilead Sciences Appoints Merdad Parsey As Chief Medical Officer

10/4/2019 10:17:50 AM FDA Approves Descovy, Second Drug To Prevent HIV Infection

9/27/2019 9:34:53 PM Biotech Stocks Facing FDA Decision In October 2019

9/9/2019 7:40:44 AM Gilead, Elton John AIDS Foundation Launch RADIAN Initiative To Address HIV

8/8/2019 5:23:05 AM DERM On Watchlist, FDA Panel Nod For GILD, So Long, CVRS And AVDR

8/6/2019 8:04:36 AM Gilead Canada: Ontario Provides Access To Biktarvy For Treatment Of HIV

7/30/2019 4:26:01 PM Gilead Sciences Inc. Q2 adjusted earnings Beat Estimates

7/30/2019 4:04:22 PM Gilead Sciences Q2 EPS $1.47 Vs. $1.39 Year Ago

7/30/2019 6:06:23 AM Gilead Sciences Q2 19 Earnings Conference Call At 4:30 PM ET

7/29/2019 7:28:28 AM Biotech Stocks Facing FDA Decision In August 2019

7/23/2019 4:14:45 PM Gilead Presents Results From Two Studies Of Investigational TLR7 Agonists

7/23/2019 11:15:40 AM Gilead Presents Findings On Profile Of Descovy For Potential Use As HIV Pre-exposure Prophylaxis Compared With Truvada

7/19/2019 8:53:11 AM Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis

7/19/2019 8:35:35 AM Gilead Sciences Licenses Three Preclinical Antiviral Programs From Novartis

7/17/2019 8:39:14 AM Chief Scientific Officer John McHutchison To Leave Gilead Sciences